Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease.

Permalink
https://escholarship.org/uc/item/3g9921m3

Journal
Journal of the American Heart Association, 8(16)

ISSN
2047-9980

Authors
Ku, Elaine
Sarnak, Mark J
Toto, Robert
et al.

Publication Date
2019-08-14

DOI
10.1161/jaha.119.012749

Peer reviewed
Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease

Elaine Ku, MD, MAS; Mark J. Sarnak, MD; Robert Toto, MD; Charles E. McCulloch, PhD; Feng Lin, MS; Miroslaw Smogorzewski, MD; Chi-yuan Hsu, MD, MSc

Background—Our objective was to explore the effect of intensive blood pressure (BP) control on kidney and death outcomes among subgroups of patients with chronic kidney disease divided by baseline proteinuria, glomerular filtration rate, age, and body mass index.

Methods and Results—We included 840 MDRD (Modification of Diet in Renal Disease) trial and 1067 AASK (African American Study of Kidney Disease and Hypertension) participants. We used Cox models to examine whether the association between intensive BP control and risk of end-stage renal disease (ESRD) or death is modified by baseline proteinuria (≥0.44 g/g), glomerular filtration rate (≥30 versus <30 mL/min per 1.73 m²), age (≥40 versus <40 years), or body mass index (≥30 versus <30 kg/m²). The median follow-up was 14.9 years. Strict (versus usual) BP control was protective against ESRD (hazard ratio [HR]ESRD, 0.77; 95% CI, 0.64–0.92) among those with proteinuria ≥0.44 g/g but not proteinuria <0.44 g/g. Strict (versus usual) BP control was protective against death (HRdeath, 0.73; 95% CI, 0.59–0.92) among those with glomerular filtration rate <30 mL/min per 1.73 m² but not glomerular filtration rate ≥30 mL/min per 1.73 m² (HRdeath, 0.98; 95% CI, 0.84–1.15). Strict (versus usual) BP control was protective against ESRD among those ≥40 years (HRESRD, 0.82; 95% CI, 0.71–0.94) but not <40 years. Strict (versus usual) BP control was also protective against ESRD among those with body mass index ≥30 kg/m² (HRESRD, 0.75; 95% CI, 0.61–0.92) but not body mass index <30 kg/m². Conclusions—The ESRD and all-cause mortality benefits of intensive BP lowering may not be uniform across all subgroups of patients with chronic kidney disease. But intensive BP lowering was not associated with increased risk of ESRD or death among any subgroups that we examined. (J Am Heart Assoc. 2019;8:e012749. DOI: 10.1161/JAHA.119.012749.)

Key Words: chronic kidney disease • end-stage renal disease • hypertension • mortality
CKD, including a higher risk for acute kidney injury, although most patients with CKD did recover from these acute kidney injury episodes, and acute kidney injury was not a primary outcome in SPRINT.\(^2,12\)

Because the duration of most clinical trials of intensive BP control have been short (mean duration, \(\approx\)3 years),\(^8\)–\(^11\) trials that are stopped early may have exaggerated effect sizes,\(^13,14\) and lower BP targets may be difficult to achieve in all patients with CKD, there is a need for longer-term studies of the effect of intensive BP control on CKD and mortality outcomes, which may occur over many years. In particular, there is a paucity of trial-based evidence to support appropriate BP targets among patients with advanced CKD (stage 4 or beyond) and among young patients with CKD (eg, 18–40 years of age) because of their underrepresentation in most clinical trials. There have also been few studies that have examined whether the effect of intensive BP lowering is more pronounced among patients who have other concurrent metabolic or cardiovascular risk factors, such as obesity, a known risk factor for both CKD progression and death.\(^15\)–\(^18\) Furthermore, current guidelines suggest that selection of BP targets be based on the estimated atherosclerotic cardiovascular disease risk, but the available risk estimators have not been validated and may not be applicable to patients <40 years of age.\(^1,19\)

The objective of this study was to explore the long-term effects of intensive BP lowering on the risk of end-stage renal disease (ESRD) or death among CKD subgroups of interest. We were specifically interested in determining: (1) the threshold of baseline proteinuria that associates with renal or mortality benefit given prior post hoc analysis of trials that have noted at least a renal benefit from intensive BP control among patients with varying degrees of proteinuria\(^20\)–\(^23\); (2) whether intensive BP lowering has differential effects on the risk of ESRD or death in those with advanced (glomerular filtration rate [GFR] \(<30\) mL/min per 1.73 m\(^2\)) versus earlier stages of CKD; and (3) whether intensive BP lowering has differential effects in younger patients (\(<40\) years of age) or among obese patients (body mass index [BMI] \(\geq30\) kg/m\(^2\)). In addition, we were also interested in whether the impact of intensive BP lowering on mortality risk was primarily noted during the CKD phase of illness versus after the onset of ESRD (overall and by subgroups of interest). To enhance our ability to perform subgroup analyses, we pooled participants from 2 completed randomized controlled trials with long-term follow-up for study: the AASK (African American Study of Kidney Disease and Hypertension) and the MDRD (Modification of Diet in Renal Disease) trial.\(^8,10,20,24\)

Methods

Study Population

AASK was a large 2 \(\times\) 3 factorial randomized controlled study that assessed the effect of strict BP control and antihypertensive agents on the progression of CKD in blacks (N=1094). Details of the trial design and results have been published.\(^10,20,24\) Between 1995 and 2001, participants between 18 and 70 years of age with measured GFR 20 to 65 mL/min per 1.73 m\(^2\) were randomized to either strict (mean arterial pressure [MAP] \(<92\) mm Hg) versus usual (MAP \(102–107\) mm Hg) BP control. Patients were also simultaneously randomized to an angiotensin-converting enzyme inhibitor (ramipril), sustained-release \(\beta\) blocker (metoprolol), or calcium channel blocker (amlodipine) as their first-line antihypertensive agent in 2:2:1 assignment, respectively. Patients with a history of malignant hypertension, diabetes mellitus, causes of renal disease other than hypertensive nephrosclerosis, pregnancy, clinical evidence of heart failure, or proteinuria \(\geq2.5\) g/d were excluded from study. At trial closure, 689 participants (of the original 1094) who had not developed ESRD or died continued in the observational cohort study, which began in April 2002 and ended June 30, 2007.\(^23,25\) All AASK cohort participants were switched as first-line therapy to an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker if angiotensin-converting enzyme inhibitor could not be tolerated with a target BP of \(<140/90\) mm Hg, which was modified in 2004 to \(<130/80\) mm Hg as a result of publication of the Joint National Committee 7 guidelines.\(^23,26\)

The MDRD trial was a large 2 \(\times\) 2 factorial design randomized controlled trial of the effect of strict BP control and dietary protein restriction on the progression of CKD (N=840). Details of the study design and results have been previously published.\(^5\) Briefly, between 1989 and 1993, CKD patients between 18 and 70 years of age with measured GFR 13 to 55 mL/min per 1.73 m\(^2\) were randomized to either strict or usual BP control.\(^8,27\) Strict BP control was defined as a target
Outcome

The primary outcomes of interest in our study were ESRD and mortality. To extend ascertainment of ESRD and vital status through 2012, we performed linkage of AASK and MDRD trial participants with the US Renal Data System, the national ESRD registry, and the national death indexes, as previously described.29–32 Patients were censored as of June 30, 2012, if they had not developed ESRD or died by this date. For this study, to ensure uniform ascertainment, we defined ESRD as receipt of chronic dialysis or kidney transplant, according to the US Renal Data System database, over the entire study duration. AASK patients without identifiers available for linkage to external databases (N=27) were excluded from analyses, leaving 1067 participants for inclusion in the present study. No MDRD trial participants were excluded from study. Institutional review board approval was obtained for data linkage at the University of California, San Francisco, and the Cleveland Clinic.

Statistical Analysis

We included 1067 AASK participants and 840 MDRD trial participants for study, and we pooled both trials for analysis to enhance generalizability and power among the subgroups of interest after testing for and finding no interaction between BP arm assignment and trial data source for both outcomes of interest. We tested for differences between characteristics of patients in subgroups of interest using $t$ tests, Wilcoxon rank-sum tests, and $\chi^2$ tests.

To preserve the original randomization scheme, all primary analyses were conducted in an intention-to-treat manner using BP arm assignment as the primary predictor, but all primary models allowed for different baseline hazards for each trial in our Cox models. Risk factors of interest that we thought could modify the effect of intensive BP control on outcomes included level of GFR $\geq$ 30 or $<30$ mL/min per 1.73 m$^2$ (according to Kidney Disease Improving Global Outcomes guidelines for CKD staging),33 age ($\geq$ 40 or $<40$ years), and BMI ($\geq$ 30 or $<30$ kg/m$^2$); these cutoffs were selected as clinically relevant thresholds for each factor of interest. Thus, we first performed stratified analysis by the risk factor of interest (eg, stage 4–5 CKD versus stage 3 CKD) using unadjusted Cox models for the outcomes of ESRD and death in separate models, pooling data from both trials and allowing separate baseline hazards for each trial. Both pre-ESRD and post-ESRD deaths were included. In Cox models with ESRD as the outcome, deaths occurring before ESRD were treated as a censoring event. In sensitivity analysis, we treated death as a competing risk in Fine-Gray models focused on ESRD. We considered unadjusted models our primary analysis given that we were testing the effect of the randomized intervention among subgroups of interest.

In secondary analysis, we repeated these analyses, adjusting for age, sex, race, measured GFR, BMI, and proteinuria category, but still allowed separate baseline hazards for each trial.

Next, we explored whether interactions were present between randomized BP goal assignment and kidney function, age, or BMI categories using our primary models for the risk of ESRD and death using pooled trial data. Tests for interaction were performed in separate models for each risk factor of interest.

We also tested for the presence of interaction between the logarithm of proteinuria (as a continuous variable) and the BP target assignment. Once we found the presence of an interaction, we determined the threshold of proteinuria at which intensive BP lowering was associated with risk of ESRD by using Cox models with 0.1g/g incremental thresholds of proteinuria to find the exact magnitude of proteinuria at which strict BP control became associated with benefit for the outcome of ESRD (ie, such that there was an interaction between BP arm assignment and proteinuria categories; Table S1). We found a difference in the risk of ESRD when proteinuria levels were $<0.44$ g/g. We then performed unadjusted and adjusted Cox models stratified by proteinuria categorized as $\geq$0.44 or $<0.44$ g/g as described above, and explored whether an interaction was present between BP arm assignment and proteinuria category.

Finally, we examined whether there was a difference in the effect of strict versus usual BP control on risk of death during the pre-ESRD phase of illness versus after the onset of ESRD.
We tested for interaction between BP arm assignment and ESRD onset (as a time-dependent covariate) for the risk of death.

We then examined the death rate during the CKD compared with the ESRD phase of illness overall and by subgroups of interest. Log-rank tests were used to determine whether the rate of death differed by BP arm assignment among all groups of interest.

All analyses were conducted using Stata 14 and verified by separate analyst using SAS. Institutional Review Board approval was obtained at University of California, San Francisco, for data linkage and secondary data analysis. Informed consent was obtained from all subjects for participation in the MDRD trial and AASK and AASK cohort studies.

Results

The baseline characteristics of MDRD trial and AASK participants included in this study (N=1907) are shown in Table 1. The mean age of participants was 53 years, median proteinuria was 0.12 g/g, and median GFR was 40 mL/min per 1.73 m² (Table 1). The characteristics of participants stratified by proteinuria, GFR, BMI, and age categories in the intensive and usual BP treatment arms are shown in Table 2.

Median follow-up starting from the time of randomization until death or administrative censoring was 14.9 (interquartile range, 9.6–15.8) years. There were 482 deaths and 526 ESRD cases among those randomized to the usual BP control arm and 438 deaths and 498 ESRD cases in the strict BP control arm. We did not find the presence of any interaction between BP arm assignment and trial data source (P>0.10) for the outcomes of ESRD or death.

Overall, there was a statistically significant benefit from strict versus usual BP control in unadjusted analysis for the outcomes of death and ESRD (Figure A and B), as previously described. Similar findings were noted in adjusted analyses for the outcome of ESRD (Table S2).

For the outcome of death, in stratified analysis, the unadjusted risk of death was lower among those assigned to strict versus usual BP control if the participant had a baseline GFR <30 mL/min per 1.73 m² (hazard ratio [HR], 0.73; 95% CI, 0.59–0.92; FigureA). In contrast, those with higher baseline GFR had no statistically significant mortality benefit from strict (versus usual) BP control (FigureA). Similarly, those with more proteinuria at baseline tended to have lower risk of death from intensive BP lowering (FigureA), although there was not a statistically significant interaction (P>0.05). Results from adjusted analyses are shown in Table S2. For the outcome of death, we noted a statistically significant interaction between BP arm assignment and GFR category (P=0.02). There appeared to be no statistically significant difference in the risk of death by baseline proteinuria, BMI category, or age category (Figure A).

For the outcome of ESRD, we found a protective effect of strict (versus usual) BP control (HR, 0.77; 95% CI, 0.64–0.92) among those with more proteinuria (FigureB). This was not seen among participants with less baseline proteinuria (HR, 0.95; 95% CI, 0.81–1.12), as would be expected given that we searched for the threshold at which effect modification was present by baseline proteinuria. There was a statistically significant beneficial effect of strict (versus usual) BP control among older participants (HR, 0.82; 95% CI, 0.71–0.94) but not among younger participants (FigureB). There was also a statistically significant beneficial effect of strict (versus usual) BP control among obese (HR, 0.75; 95% CI, 0.61–0.92) but not among nonobese participants (FigureB). Results from adjusted analyses are shown in Table S2. The effect of strict BP control appeared to differ depending on age category (P=0.006 for interaction) and BMI category (P=0.03 for test for interaction), but not baseline GFR (P=0.87 for test for interaction) in unadjusted analysis.

In sensitivity analysis, even after accounting for the competing risk of death in Fine-Gray models, strict (versus usual) BP control was associated with a lower risk of ESRD among those with more proteinuria, older age, or obesity at baseline (Table 3).

Finally, we examined the risk of death before versus after the onset of ESRD. Death rates were 2- to 3-fold higher after onset of ESRD than during the CKD phase of illness (Table 4). Differences in death rates among those assigned to strict versus usual BP control were more pronounced after ESRD.

Table 1. Overall Characteristics of MDRD Trial and AASK Participants at Baseline (N=1907)

| Characteristic                | Value       |
|------------------------------|-------------|
| Age, y                       | 53±11       |
| Women                        | 746 (39)    |
| Black                        | 1133 (59)   |
| Baseline MAP, mm Hg          | 107±16      |
| Baseline proteinuria, g/d    | 0.12 (0.04–0.62) |
| Baseline GFR, mL/min per 1.73 m² | 40 (28–52) |
| Baseline BMI, kg/m²          | 29±6        |
| Assignment to strict BP control | 954 (50)   |
| Assignment to ACE inhibitor in AASK only | 425/1067 (40) |

Data are given as mean±SD, number (percentage), or median (interquartile range). AASK indicates African American Study of Kidney Disease and Hypertension; ACE, angiotensin-converting enzyme; BMI, body mass index; BP, blood pressure; GFR, glomerular filtration rate; MAP, mean arterial pressure; MDRD, Modification of Diet in Renal Disease.

DOI: 10.1161/JAHA.119.012749 Journal of the American Heart Association 4
onset compared with during the CKD phase of illness (Table 4).

**Discussion**

In this study, we pooled 2 completed trials of intensive BP lowering to examine its effect on risk of ESRD or death on the basis of baseline proteinuria, GFR, age, and BMI. For the outcome of mortality, we found that intensive BP control was especially beneficial among those with lower GFR at baseline. For the outcome of ESRD, intensive BP lowering was especially beneficial among those with more baseline proteinuria, older age, and higher BMI. We identified that presence of $\geq 0.44$ g/g of proteinuria may help identify individuals who may especially benefit from intensive BP lowering. We also found that intensive BP lowering appeared to have particularly large benefits for the risk of death after the onset of ESRD, as opposed to during the CKD phase of illness. We believe our study is unique in its

### Table 2. Baseline Characteristics by CKD Subgroups of Interest

| Characteristic                                      | Usual BP | Strict BP | P Value | Usual BP | Strict BP | P Value |
|-----------------------------------------------------|----------|-----------|---------|----------|-----------|---------|
| Proteinuria, g/g                                    | $<0.44$  | $\geq 0.44$ | 0.86    | $50\pm 12$ | $50\pm 13$ | 0.53    |
| Age, y                                              | $55\pm 11$ | $54\pm 11$ | 0.45    | $126 (42)$ | $95 (33)$ | 0.02    |
| Women                                               | 254 (39) | 271 (41)  | 0.36    | 143 (48)  | 132 (46)  | 0.55    |
| Black                                               | 434 (66) | 424 (64)  | 0.57    | $107\pm 15$ | $108\pm 15$ | 0.36    |
| Baseline MAP, mm Hg                                 | 107 (15) | $107\pm 17$ | 0.29    | 28 (22–38) | 31 (23–44) | 0.03    |
| Baseline proteinuria, g/d                           | 0.06 (0.03–0.12) | 0.06 (0.03–0.14) | 0.54    | 1.19 (0.71–1.87) | 1.11 (0.68–1.82) | 0.78    |
| BMI, kg/m$^2$                                       | $28 (25–32)$ | $28 (25–32)$ | 0.39    | $28 (25–33)$ | $28 (24–32)$ | 0.72    |
| GFR, mL/min per 1.73 m$^2$                          | $>30$    | $<30$     | 0.42    | $52\pm 12$ | $50\pm 13$ | 0.03    |
| Age, y                                              | $54\pm 11$ | $54\pm 11$ | 0.74    | $130 (44)$ | $108 (41)$ | 0.57    |
| Women                                               | 250 (38) | 258 (37)  | 0.42    | 114 (38)  | 81 (31)   | 0.07    |
| Black                                               | 463 (71) | 475 (69)  | 0.22    | $104\pm 14$ | $103\pm 15$ | 0.51    |
| Baseline proteinuria, g/d                           | 0.07 (0.03–0.29) | 0.07 (0.03–0.36) | 0.40    | 0.59 (0.12–1.44) | 0.46 (0.13–1.41) | 0.82    |
| BMI, kg/m$^2$                                       | $29 (25–33)$ | $29 (25–33)$ | 0.73    | $27 (24–31)$ | $26 (23–30)$ | 0.06    |
| Age category, y                                      | $<40$    | $\geq 40$ | 0.97    | $56\pm 8$  | $56\pm 9$  | 0.76    |
| Age, y                                              | $33\pm 5$ | $33\pm 5$  | 0.053   | $323 (39)$ | $319 (39)$ | 0.96    |
| Women                                               | 57 (45)  | 47 (33)   | 0.69    | 519 (63)  | 495 (61)  | 0.42    |
| Black                                               | 58 (46)  | 61 (43)   | 0.22    | $107\pm 15$ | $108\pm 15$ | 0.68    |
| Baseline proteinuria, g/d                           | 0.37 (0.09–1.21) | 0.40 (0.1–1.29) | 0.34    | 0.10 (0.03–0.54) | 0.10 (0.03–0.49) | 0.55    |
| Baseline GFR, mL/min per 1.73 m$^2$                  | $37 (27–48)$ | $32 (24–47)$ | 0.12    | 40 (28–53) | 42 (30–53) | 0.29    |
| BMI, kg/m$^2$                                       | $26 (23–30)$ | $27 (23–33)$ | 0.20    | $28 (25–33)$ | $28 (25–32)$ | 0.26    |
| BMI category, kg/m$^2$                              | $<30$    | $\geq 30$ | 0.93    | $54\pm 10$ | $53\pm 11$ | 0.51    |
| Age, y                                              | $53\pm 12$ | $53\pm 12$ | 0.52    | 145 (42)  | 147 (41)  | 0.77    |
| Women                                               | 235 (39) | 219 (37)  | 0.33    | 262 (76)  | 265 (74)  | 0.51    |
| Black                                               | 315 (52) | 291 (49)  | 0.91    | $110\pm 15$ | $112\pm 17$ | 0.14    |
| Baseline proteinuria, g/d                           | 0.11 (0.04–0.65) | 0.11 (0.04–0.63) | 0.64    | 0.12 (0.03–0.65) | 0.14 (0.04–0.55) | 0.58    |
| Baseline GFR, mL/min per 1.73 m$^2$                  | $37 (26–50)$ | $38 (26–50)$ | 0.85    | 44 (31–55) | 45 (34–54) | 0.43    |
| BMI, kg/m$^2$                                       | $26 (24–28)$ | $26 (23–28)$ | 0.11    | $35 (32–38)$ | $34 (32–38)$ | 0.26    |

Data are given as column mean±SD, number (percentage), or median (interquartile range). BMI indicates body mass index; BP, blood pressure; CKD, chronic kidney disease; GFR, glomerular filtration rate; MAP, mean arterial pressure.
A

Risk of Death in AASK and MDRD

* p<0.05 for interaction

| MDRD and AASK N=1907 | N   | Number of deaths | Usual BP Death per 100 person-years | Strict BP Death per 100 person-years | Unadjusted HR (95% CI) Strict vs Usual |
|----------------------|-----|------------------|-------------------------------------|-------------------------------------|---------------------------------------|
| Overall              | 1907| 920              | 3.7                                 | 3.3                                 | 0.87 (0.76-0.99)                      |
| Urine protein < 0.44 g/day | 1319| 591              | 3.3                                 | 3.1                                 | 0.93 (0.79-1.09)                      |
| Urine protein ≥ 0.44 g/day | 588 | 329              | 4.7                                 | 3.7                                 | 0.77 (0.62-0.96)                      |
| GFR ≥ 30 mL/min/1.73 m² | 343 | 592              | 3.2                                 | 3.1                                 | 0.98 (0.84-1.15)                      |
| GFR < 30 mL/min/1.73 m² | 249 | 328              | 5.0                                 | 3.6                                 | 0.73 (0.59-0.92)                      |
| Age <40 years         | 268 | 53               | 1.1                                 | 1.2                                 | 1.02 (0.60-1.76)                      |
| Age ≥ 40 years        | 1639| 867              | 4.3                                 | 3.7                                 | 0.86 (0.75-0.98)                      |
| BMI <30 kg/m²         | 1204| 578              | 3.6                                 | 3.1                                 | 0.85 (0.72-1.00)                      |
| BMI ≥ 30 kg/m²        | 702 | 341              | 3.9                                 | 3.5                                 | 0.88 (0.71-1.09)                      |

B

Risk of ESRD in AASK and MDRD

* p<0.05 for interaction

| MDRD and AASK N=1907 | N   | Number of ESRD events | Usual BP ESRD per 100 person-years | Strict BP ESRD per 100 person-years | Unadjusted HR (95% CI) Strict vs Usual |
|----------------------|-----|-----------------------|------------------------------------|-------------------------------------|---------------------------------------|
| Overall              | 1907| 1024                  | 6.0                                | 5.4                                 | 0.88 (0.78-1.00)                      |
| Urine protein < 0.44 g/day | 1319| 569                   | 4.0                                | 4.0                                 | 0.95 (0.81-1.12)                      |
| Urine protein ≥ 0.44 g/day | 588 | 455                   | 14.1                               | 10.8                                | 0.77 (0.64-0.92)                      |
| GFR ≥ 30 mL/min/1.73 m² | 1349| 572                   | 4.0                                | 3.7                                 | 0.90 (0.77-1.06)                      |
| GFR < 30 mL/min/1.73 m² | 558 | 452                   | 14.6                               | 14.4                                | 0.95 (0.79-1.15)                      |
| Age <40 years         | 268 | 213                   | 9.1                                | 11.0                                | 1.23 (0.94-1.61)                      |
| Age ≥ 40 years        | 1639| 811                   | 5.5                                | 4.7                                 | 0.82 (0.71-0.94)                      |
| BMI <30 kg/m²         | 1204| 665                   | 6.0                                | 5.9                                 | 0.96 (0.83-1.12)                      |
| BMI ≥ 30 kg/m²        | 702 | 358                   | 6.0                                | 4.7                                 | 0.75 (0.61-0.92)                      |

Figure. A, Unadjusted risk of death by blood pressure (BP) arm assignment comparing strict vs usual BP control. B, Unadjusted risk of end-stage renal disease (ESRD) by BP arm assignment comparing strict vs usual BP control. AASK indicates African American Study of Kidney Disease and Hypertension; BMI, body mass index; GFR, glomerular filtration rate; HR, hazard ratio; MDRD, Modification of Diet in Renal Disease.

DOI: 10.1161/JAHA.119.012749

Journal of the American Heart Association
Table 3. Risk of ESRD Accounting for the Competing Risk of Death

| Variable                          | Unadjusted Sub-HR (95% CI)          |
|-----------------------------------|-------------------------------------|
| MDRD Trial and AASK (N=1907)      |                                     |
| Overall                           | 0.90 (0.80–1.02)                    |
| Urine protein <0.44 g/g*          | 0.99 (0.84–1.17)                    |
| Urine protein ≥0.44 g/g*          | 0.76 (0.63–0.91)                    |
| GFR ≥30 mL/min per 1.73 m²        | 0.94 (0.80–1.10)                    |
| GFR <30 mL/min per 1.73 m²        | 0.93 (0.77–1.12)                    |
| Age <40 y*                        | 1.18 (0.90–1.54)                    |
| Age ≥40 y*                        | 0.85 (0.74–0.98)                    |
| BMI <30 kg/m²                      | 0.97 (0.83–1.13)                    |
| BMI ≥30 kg/m²                      | 0.79 (0.65–0.98)                    |

AASK indicates African American Study of Kidney Disease and Hypertension; BMI, body mass index; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HR, hazard ratio; MDRD, Modification of Diet in Renal Disease.

*P<0.05 for interaction.

The provision of long-term follow-up that extends beyond the mean duration of most clinical trials (2–3 years).

In contrast to large observational studies suggesting that lower BP levels are associated with higher risk of mortality in patients with CKD,34,35 we did not find evidence of harm in any subgroups explored when this intervention was tested in a randomized trial. We found the effect of intensive BP lowering to be especially protective from a mortality standpoint among patients with advanced CKD and, therefore, greater derived benefit from intensive BP lowering and its cardiovascular benefits, although we are limited in the lack of data on cardiovascular events posttrial closure.2 Intensive BP lowering during the CKD phase of illness may also serve to improve the cardiovascular health of patients once they transition to ESRD and, thereby, lower the risk of death after onset of ESRD (when cardiovascular mortality risk is at its peak).31 Our data offer reassurance that intensive BP lowering did not appear to be associated with harm in any of the subgroups we analyzed in the trial settings and are overall consistent with the results of SPRINT, although the MDRD trial and AASK enrolled a population with greater severity of kidney disease and proteinuria compared with SPRINT and targeted MAP as opposed to systolic BP.

Although a few prior post hoc analyses of clinical trials have suggested a renal benefit with an intensive BP-lowering strategy among patients with significant proteinuria, most of these studies have focused on change in the slope of kidney function decline as an outcome and not ESRD onset.

Recent studies have suggested that slopes of renal function decline or albuminuria may not be associated with risk of ESRD as strongly as would be needed for these outcomes to serve as surrogate endpoints.37 In prior post hoc trial analyses and meta-analyses, the level of proteinuria needed for intensive BP lowering to be associated with renal benefit varied considerably and ranged from a protein/creatinine ratio of 0.22 to 1.5 g/g.21,23,36,38,39 In our study, we found that proteinuria ≥0.44 g/g may serve as a threshold that identifies patients who would benefit from intensive BP control because of the presence of proteinuria.

We note that there was significant heterogeneity in the effect of intensive BP lowering, depending on the characteristics of patients at baseline enrollment into the MDRD trial and AASK. Traditionally, most trials have not routinely reported the heterogeneity in the effect of the intervention being tested by baseline risk for outcomes of interest.40,41 A network meta-analysis of randomized trials recently

Table 4. Death Rate Before and After ESRD by Subgroups of Interest

| Variable                          | Death Rate (per 100-Person Years) During CKD (95% CI) | Death Rate (per 100-Person Years) during ESRD (95% CI) |
|-----------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                  | Usual BP Strict BP                                    | Usual BP Strict BP                                    |
| Overall                           | 2.1 (1.8–2.4) 2.2 (1.9–2.5)                           | 7.1 (6.4–8.0) 5.6 (4.9–6.3)*                           |
| Urine protein <0.44 g/d           | 2.2 (1.9–2.6) 2.1 (1.8–2.5)                           | 7.2 (6.1–8.4) 6.2 (5.2–7.3)                           |
| Urine protein ≥0.44 g/d           | 1.7 (1.2–2.5) 3.1 (2.8–3.5)                           | 7.1 (6.0–8.3) 4.9 (4.0–6.0)*                           |
| GFR ≥30 mL/min per 1.73 m²        | 2.2 (1.9–2.5) 2.2 (1.9–2.5)                           | 6.9 (5.8–8.2) 6.8 (5.7–8.0)                           |
| GFR <30 mL/min per 1.73 m²        | 1.7 (1.2–2.5) 3.1 (2.8–3.5)                           | 7.3 (6.3–8.5) 4.5 (3.7–5.5)*                           |
| Age <40 y                         | 0.5 (0.2–1.2) 0.8 (0.4–1.5)                           | 1.8 (1.1–2.8) 1.4 (0.9–2.2)                           |
| Age ≥40 y                         | 2.3 (2.0–2.7) 2.3 (2.0–2.7)                           | 9.0 (8.0–10.2) 7.6 (6.6–8.7)                           |
| BMI <30 kg/m²                      | 2.1 (1.7–2.5) 2.3 (1.9–2.7)                           | 6.7 (5.8–7.7) 4.6 (3.9–5.4)*                           |
| BMI ≥30 kg/m²                      | 2.1 (1.7–2.7) 2.0 (1.6–2.6)                           | 8.1 (6.7–9.8) 8.1 (6.6–9.9)                           |

BMI indicates body mass index; BP, blood pressure; CKD, chronic kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate.

*Statistically significantly different comparing strict vs usual BP arm assignment (P<0.05).
demonstrated that, although intensive BP lowering was effective in reducing the risk of cardiovascular outcomes, the risk of serious adverse events was higher with lower BP targets.42 Our study explores patient characteristics that would favor intensification of BP control (eg, those with advanced CKD for survival benefit and those who are older, are obese, or have proteinuria for reduction in ESRD risk).

The strengths of our study include the large number of ESRD events and deaths and the availability of nearly 2 decades of follow-up in AASK and MDRD trial participants. In addition, we provide pooled data from 2 separate trials with a racially diverse group of participants and are able to provide data on the effect of an intervention delivered pre-ESRD on outcomes after the onset of ESRD.

However, there are several limitations to our study. Our results may not apply to people with CKD attributed to diabetes mellitus. Although we had prespecified interest in the subgroups divided by GFR, BMI, and age thresholds, we recognize the potential for multiple hypothesis testing and that not all risk factors were noted to be statistically significant effect modifiers. We do not have detailed data surrounding cardiovascular events (eg, stroke or new-onset heart failure) that may have developed with each of the treatment strategies during long-term follow-up. We acknowledge that our study is post hoc and observational and that our results may reflect the “legacy effect”43 of BP lowering during these trials. Because of this, we believe that the findings in our study likely underestimate the true potential impact of intensive BP lowering, given the likely convergence of BP levels between the strict and usual BP arms posttrial closure, which would have attenuated the effects that we report and were most of our follow-up period.

In recognition of the challenges of achieving adequate BP control in the CKD population,44–46 targeting patients who may have the greatest kidney and mortality benefits for the achievement of aggressive BP lowering is important. We suggest that patients with more proteinuria (>0.44 g/g) may particularly benefit from achievement of lower BP targets. Long-term benefits of intensive BP lowering after the transition from CKD to ESRD may also be a factor for consideration when selecting BP treatment targets. Further studies are needed to individualize the approach to BP target selection and balance the risk of ESRD with that of mortality and other adverse effects of treatment.

Acknowledgments

Research idea and study design: Drs Ku and Hsu; data acquisition: Drs Ku, Sarnak, Toto, Smogorzewski, and Hsu; data analysis/interpretation: Drs Ku, Sarnak, Toto, Smogorzewski, McCulloch, and Hsu and F. Lin; statistical analysis: Drs Ku, McCulloch, and Hsu and F. Lin. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Sources of Funding

This work was supported by the National Institutes of Health (NIH) (K23 HL131023 to Ku and K24 DK92291 to Hsu). The funding source did not have any role in manuscript preparation. The AASK (African American Study of Kidney Disease and Hypertension) and MDRD (Modification of Diet in Renal Disease) trial were conducted by AASK and MDRD trial investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the AASK and MDRD trial reported herein were supplied in part by the NIDDK Central Repositories. This manuscript does not necessarily reflect the opinions or views of the AASK and MDRD trial and cohort studies, the NIDDK Central Repositories, or the NIDDK grants MD000182, UL1TR000124, and P30AG021684. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The interpretation and reporting of the data presented herein are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government.

Disclosures

None.

References

1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPAM/AGS/APHAA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2017;72:e33.

2. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Rebourssin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Golf DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116.

3. Greenland P, Peterson E. The new 2017 ACC/AHA guidelines “up the pressure” on diagnosis and treatment of hypertension. JAMA. 2017;318:2083–2084.

4. Bhatt H, Ghazi L, Calhoun D, Oparil S. BP targets in hypertension: what should we do now that sprint is out? Curr Cardiof Rep. 2016;18:98.

5. Chertow GM, Beddu S, Lewis JS, Toto RD, Cheung AK. Managing hypertension in patients with CKD: a marathon, not a sprint. J Am Soc Nephrol. 2016;27:40–43.

6. de Boer IH, Bakris G, Cannon CP. Individualizing blood pressure targets for people with diabetes and hypertension: comparing the ADA and the ACC/AHA recommendations. JAMA. 2018;319:1319–1320.

7. Cheung AK, Rahman M, Rebourssin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT Jr, Basile J, Beddu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Riccio AC, Servilla K, Wall B, Wolfgram D, Yee J. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28:2812–2823.
41. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.src Trials. 2010;11:85.

42. Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G, Messerli FH. Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017;130:707–719.e8

43. Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, Karter AJ. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the diabetes & aging study). Diabetes Care. 2019;42:416–426.

44. Plantinga LC, Miller ER III, Stevens LA, Saran R, Messer K, Flowers N, Geiss L, Powe NR; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999–2006. Hypertension. 2009;54:47–56.

45. Sarafidis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, Bakris GL. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008;121:332–340.

46. Owen WF Jr. Patterns of care for patients with chronic kidney disease in the united states: dying for improvement. J Am Soc Nephrol. 2003;14:S76–S80.
SUPPLEMENTAL MATERIAL
Table S1. Thresholds for statistically significant interaction between BP arm assignment and baseline proteinuria for the outcome of ESRD.

| MDRD and AASK N=1907 | P-value |
|----------------------|---------|
| Urine protein < 0.3 g/g (versus ≥ 0.3 g/g) | 0.09 |
| Urine protein < 0.4 g/g (versus ≥ 0.4 g/g) | 0.07 |
| Urine protein < 0.43 g/g (versus ≥ 0.43 g/g) | 0.056 |
| Urine protein < 0.44 g/g (versus ≥ 0.44 g/g) | 0.044 |
| Urine protein < 0.45 g/g (versus ≥ 0.45 g/g) | 0.04 |
| Urine protein < 0.5 g/g (versus ≥ 0.5 g/g) | 0.02 |
| Urine protein < 0.6 g/g (versus ≥ 0.6 g/g) | 0.02 |
**Table S2.** Risk of ESRD or death in Cox models comparing strict versus usual BP arms (HR = hazard ratio).

|                      | Death |                      | ESRD |                      |
|----------------------|-------|----------------------|------|----------------------|
|                      | N     | Unadjusted HR (95% CI)| Adjusted* HR (95% CI) | Unadjusted HR (95% CI) | Adjusted* HR (95% CI) |
| MDRD and AASK N=1907 |       |                      |      |                      |
| Overall              | 1907  | 0.87 (0.76-0.99)     | 0.85 (0.75-0.97)       | 0.88 (0.78-1.00)       | 0.88 (0.78-0.99)       |
| Urine protein < 0.44 g/day | 1319  | 0.93 (0.79-1.09)     | 0.93 (0.79-1.09)       | 0.95 (0.81-1.12)       | 0.96 (0.81-1.13)       |
| Urine protein ≥ 0.44 g/day | 588   | 0.77 (0.62-0.96)     | 0.77 (0.61-0.96)       | 0.77 (0.64-0.92)       | 0.79 (0.65-0.96)       |
| GFR ≥ 30 mL/min/1.73 m² | 1349  | 0.98 (0.84-1.15)     | 0.90 (0.77-1.06)       | 0.90 (0.77-1.06)       | 0.88 (0.75-1.04)       |
| GFR < 30 mL/min/1.73 m² | 558   | 0.73 (0.59-0.92)     | 0.82 (0.66-1.03)       | 0.95 (0.79-1.15)       | 0.92 (0.76-1.11)       |
| Age <40 years        | 268   | 1.02 (0.60-1.76)     | 0.88 (0.51-1.53)       | 1.23 (0.94-1.61)       | 1.00 (0.76-1.33)       |
| Age ≥ 40 years       | 1639  | 0.86 (0.75-0.98)     | 0.88 (0.77-1.01)       | 0.82 (0.71-0.94)       | 0.85 (0.74-0.98)       |
| BMI < 30 kg/m²       | 1204  | 0.85 (0.72-1.00)     | 0.86 (0.73-1.01)       | 0.96 (0.83-1.12)       | 0.98 (0.84-1.15)       |
| BMI ≥ 30 kg/m²       | 702   | 0.88 (0.71-1.09)     | 0.90 (0.73-1.11)       | 0.75 (0.61-0.92)       | 0.67 (0.54-0.82)       |

*Adjusted for age, sex, race, proteinuria (≥ versus < 0.5 g/g), GFR (≥ 30 versus < 30 mL/min/1.73 m²), BMI, and stratified for trial data source.